CytoDel

Market position

The company positions its recombinant platform relative to established fermentation-derived botulinum toxin pharmaceuticals such as Botox (AbbVie/Allergan).

All currently FDA-approved botulinum toxin pharmaceutical products are produced by fermentation of native Clostridium botulinum serotype A1 and share the same active ingredient, differing only in excipients, production and analytical methods, and approved indications. CytoDel instead engineers recombinant, atoxic BoT derivatives whose toxicity-driving protease is inactivated, preserving neuronal uptake and trafficking while enabling intracellular delivery of therapeutic protein payloads with an indication-specific safety profile.

Technology

Recombinant protein engineering produces rBoT derivatives that retain native botulinum toxin's ability to enter and traffic within neurons but have the toxicity-causing protease inactivated, turning the toxin into a delivery vehicle for therapeutic protein payloads into the neuronal cytoplasm.

Go-to-market

Patients with neuromuscular and other peripheral and central nervous system conditions of high unmet medical need, plus musculoskeletal and aesthetic medicine applications.

Geography

Operations have been based in New York, with R&D conducted at the Harlem Biospace incubator and origins tied to NYU.

History

The company was formed as CytoDel, LLC to commercialize technology developed by its founders at NYU. It participated in the NYU Venture Fellows program and established R&D operations at Harlem Biospace, a biotechnology incubator. By late 2014 it had completed an initial round of financing and had been awarded a Phase I SBIR grant of approximately $225,000 to study a recombinant botulinum neurotoxin for neuromuscular disease and as a potentially safer alternative to existing aesthetic-medicine products.